Bioxyne FCF Margin
The Free Cash Flow Margin of Bioxyne (BXN.AX) as of Aug 1, 2026 is 14.80 %. In the previous year, Free Cash Flow Margin was -43.46 % — a change of -134.05% (higher).
Get this data via API
Financial Data API
FCF Margin
14.80 %
YoY
-134.05%
Last updated:
Free Cash Flow Margin of Bioxyne is 2026 14.80 % . Free Cash Flow Margin of Bioxyne was 2025 -43.46 % . It decreases by -134.05% higher compared to the previous year.
Access this data via the Eulerpool API
Bioxyne Stock analysis
What does Bioxyne do? Bioxyne Ltd is an Australian biotechnology company that was founded in 2000. Bioxyne's business model focuses on the discovery, development, and marketing of innovative, turnkey biological products and services to improve consumers' health and well-being.
Bioxyne has four different business divisions: natural products, health and wellness products, veterinary products, and contract research services. In the natural products division, Bioxyne offers a portfolio of products based on natural ingredients, such as probiotics, superfood powders, herbal extracts, and dietary supplements. These products are designed to strengthen the immune system, promote gut health and digestion, and support a healthy lifestyle.
Bioxyne's health and wellness product division offers a wide range of innovative products aimed at improving the health and well-being of people, such as vitamins, dietary supplements, skincare products, and anti-aging products. Bioxyne utilizes the latest biotechnological research to manufacture these products tailored to the needs of customers worldwide.
The veterinary product division of Bioxyne is dedicated to improving the health and well-being of pets, livestock, and other animals. Bioxyne offers a wide range of animal health products, including dietary supplements to enhance immune system and skin and hair health, as well as products supporting digestion, metabolism, and cognitive functions in animals.
Bioxyne's contract research service division specializes in providing customized and turnkey biological services and products to customers in the pharmaceutical industry, food industry, and veterinary medicine. Bioxyne has an experienced team of scientists and researchers specialized in conducting research and development services in the field of biotechnology.
Some of Bioxyne's notable products include the probiotic Nuflora, used to support and improve gut health, the natural dietary supplement Ceramosides, which has strong anti-aging effects due to its formula, and the superfood powder blend Health 365, which contains all the essential nutrients needed to support a healthy lifestyle.
Overall, Bioxyne offers a wide range of biotechnological products and services tailored to the needs of customers worldwide. The company is committed to incorporating the latest biotechnological advancements into its products and offering its customers innovative and high-quality solutions to improve health and well-being. Bioxyne is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Bioxyne stock
Free Cash Flow Margin of Bioxyne is 14.80 % in 2026.
Access this data via the Eulerpool API
Margins — Bioxyne
All Key Metrics — Bioxyne
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth